Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-014 to treat gastric ulcers in horses; epoCat, a feline recombinant erythropoietin for the management of anemia in cats; KIND-011, a monoclonal antibody that targets sick or septic foals; and KIND-509, an antibody for canine inflammatory bowel disease. Further, it is developing KIND-015 for the management of clinical signs associated with equine metabolic syndrome and anti-tumor necrosis factor in septic foals; KIND-502, an IgE antibody that targets the canine counterpart of the human target for allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; and various antibodies that target cytokines involved in atopic dermatitis, as well as interleukin antibodies and canine checkpoint inhibitors. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-701-7901
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.97 million
Profitability
Miscellaneous
Employees146
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences Inc (NASDAQ:KIN) announced its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.01. The biopharmaceutical company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $1.95 million. View Kindred Biosciences' Earnings History.
When is Kindred Biosciences' next earnings date?
What price target have analysts set for KIN?
9 equities research analysts have issued twelve-month price targets for Kindred Biosciences' shares. Their forecasts range from $11.00 to $25.00. On average, they expect Kindred Biosciences' share price to reach $16.8571 in the next year. This suggests a possible upside of 98.3% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.
What is the consensus analysts' recommendation for Kindred Biosciences?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.
What are Wall Street analysts saying about Kindred Biosciences stock?
Here are some recent quotes from research analysts about Kindred Biosciences stock:
- 1. According to Zacks Investment Research, "Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. " (5/18/2019)
- 2. Cantor Fitzgerald analysts commented, "We believe KIN’s pipeline of novel animal health drugs will drive long-term shareholder value. As KIN advances its pipeline, we think investors should begin to appreciate the peak revenue potential of the products the company brings to market. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $25 price target. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $25 price target." (4/26/2019)
- 3. HC Wainwright analysts commented, "We maintain our Buy rating of KIN and our 12-month price target of $19.00 per share. We derive our price target based on a risk-adjusted net present value analysis of projected product revenues through 2027 assuming a 10% discount rate and 3% terminal growth rate. We derive an rNPV of $603M for the pipeline products and add in $120M in pro forma cash and cash equivalents to arrive at a 12-month price target of $18.74 per diluted share, which we round to $19.00. Risks: (1) clinical and regulatory; (2) commercial; (3) partnership; (4) financial; and (5) intellectual property." (3/7/2019)
Has Kindred Biosciences been receiving favorable news coverage?
News coverage about KIN stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kindred Biosciences earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include Opko Health (OPK), Aimmune Therapeutics (AIMT), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), Epizyme (EPZM), Eidos Therapeutics (EIDX), Theravance Biopharma (TBPH), Clementia Pharmaceuticals (CMTA), Ra Pharmaceuticals (RARX), Amphastar Pharmaceuticals (AMPH), Inflarx (IFRX), Deciphera Pharmaceuticals (DCPH) and Radius Health (RDUS).
What other stocks do shareholders of Kindred Biosciences own?
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
- Ms. Denise M. Bevers, Co-Founder, Pres, COO, Sec. & Director (Age 52)
- Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
- Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
- Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations
Who are Kindred Biosciences' major shareholders?
Kindred Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Park West Asset Management LLC (17.29%), BlackRock Inc. (5.05%), Dimensional Fund Advisors LP (3.45%), Renaissance Technologies LLC (3.13%), Morgan Stanley (2.91%) and Northern Trust Corp (1.08%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Which major investors are selling Kindred Biosciences stock?
KIN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Connor Clark & Lunn Investment Management Ltd., Wells Fargo & Company MN, New York State Common Retirement Fund and B. Riley Financial Inc.. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.
Which major investors are buying Kindred Biosciences stock?
KIN stock was acquired by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, BlackRock Inc., Renaissance Technologies LLC, Rubric Capital Management LP, Sit Investment Associates Inc., Geode Capital Management LLC, Northern Trust Corp and Granite Investment Partners LLC. View Insider Buying and Selling for Kindred Biosciences.
How do I buy shares of Kindred Biosciences?
Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of KIN stock can currently be purchased for approximately $8.50.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $331.54 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.
What is Kindred Biosciences' official website?
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
